Exacerbation Study (INVIGORATE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00845728
First received: February 15, 2009
Last updated: September 16, 2013
Last verified: September 2013
  Purpose

This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Indacaterol 150 µg
Drug: Tiotropium
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIIb Multicenter, 52 Week Treatment, Randomized, Blinded, Double Dummy, Parallel Group Efficacy Study Comparing the Effect of Inhaled Indacaterol 150 µg o.d. vs Inhaled Tiotropium 18 µg o.d. on Lung Function, Rate of Exacerbations and Related Outcomes in Patients With COPD

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Trough Forced Expiratory Volume in 1 Second (FEV1). [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The primary objective of the study was to demonstrate the non-inferiority of indacaterol vs. tiotropium with respect to 24 hour post dose (trough) FEV1 after 12 weeks of treatment in patients with severe COPD. Trough FEV1 was defined as the average of the 23 hours 10 min and the 23 hours 45 min post dose values. Trough FEV1 was analyzed using a mixed model for the PPS-S. The model contained treatment as a fixed effect with the baseline FEV1, FEV1 prior to inhalation and FEV1 15 min post-inhalation of salbutamol/albuterol (components of SABA reversibility at Visit 2), FEV1 prior to inhalation and FEV1 60 min post-inhalation of ipratropium (components of anti-cholinergic reversibility at Visit 3) as covariates. Smoking history (current or ex-smoker) was included as a factor in the model.


Secondary Outcome Measures:
  • Rate of COPD Exacerbations [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    COPD exacerbations were defined as :Worsening of 2 or more major symptoms for at least 2 consecutive days: dyspnea; sputum volume; suputum purulence AND requiring treatment with systemic corticosteroids and/or antibiotics OR Worsening of any 1 major symptom together with any 1 of the following minor symptoms for at least 2 consecutive days: Sore throat; colds; fever without other cause; increased cough; increase wheeze AND requiring treatment with systemic glucocorticosteroids and/or antibiotics. The rate was analyzed using a linear model assuming a negative binomial distribution for the PPS-E. The time at risk for a patient was defined as the length of time the patient was in the study and the log(length of time in the study) was used as the offset variable in the model.


Enrollment: 3439
Study Start Date: March 2009
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Indacaterol
Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
Drug: Indacaterol 150 µg
Indacaterol 150 µg o.d. delivered via SDDPI
Active Comparator: Tiotropium
Tiotropium 18 µg o.d. delivered via the handihaler®
Drug: Tiotropium
Tiotropium 18 µg o.d. delivered via handihaler®

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female adults aged ≥40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure
  • Patients diagnosed with COPD at age 40 and over and with a current diagnosis of severe COPD and including:

    1. Smoking history of at least 10 pack years, both current and ex-smokers are eligible
    2. A documented history of at least 1 moderate or severe exacerbation in the previous 12 months

Exclusion Criteria:

  • Patients who have received systemic corticosteroids and/or antibiotics for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period
  • Patients who have had a respiratory tract infection within 6 weeks prior to screening
  • Patients with concomitant pulmonary disease
  • Patients with a history of asthma
  • Patients with diabetes Type I or uncontrolled diabetes Type II
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular comorbid conditions

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00845728

  Hide Study Locations
Locations
Argentina
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina, C1424BSF
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina, 7600
Novartis Investigative Site
Pilar, Buenos Aires, Argentina, B1629AHJ
Novartis Investigative Site
Rosario, Santa Fe, Argentina, C2000DSR
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S2000AYW
Novartis Investigative Site
San Miguel de Tucuman, Tucuman, Argentina, 4000
Novartis Investigative Site
Buenos aires, Argentina, C1221ADC
Novartis Investigative Site
Buenos Aires, Argentina, 5000
Novartis Investigative Site
Buenos Aires, Argentina, C1122AAK
Novartis Investigative Site
Buenos Aires, Argentina, C1426ABP
Novartis Investigative Site
Buenos Aires, Argentina, B1842DID
Novartis Investigative Site
Buenos Aires, Argentina, C1125ABE
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Mendoza, Argentina, M5500CCG
Australia, New South Wales
Novartis Investigative Site
Bankstown, New South Wales, Australia, 2200
Australia, South Australia
Novartis Investigative Site
Adelaide, South Australia, Australia, 5000
Novartis Investigative Site
Daw Park, South Australia, Australia, 5041
Australia, Victoria
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Novartis Investigative Site
Parkville, Victoria, Australia, 3050
Australia, Western Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia, 6009
Australia
Novartis Investigative Site
Tauranga, New Zealand, Australia, 3001
Austria
Novartis Investigative Site
Feldbach, Austria, 8330
Novartis Investigative Site
Grieskirchen, Austria, 4710
Novartis Investigative Site
Gänserndorf, Austria, 2230
Novartis Investigative Site
Hallein, Austria, 5400
Novartis Investigative Site
Linz, Austria, 4020
Novartis Investigative Site
Perg, Austria, 4320
Novartis Investigative Site
Zwettl, Austria, 3910
Belgium
Novartis Investigative Site
Aalst, Belgium, 9300
Novartis Investigative Site
Antwerpen, Belgium, 2020
Novartis Investigative Site
Bruxelles, Belgium, 1200
Novartis Investigative Site
Bruxelles, Belgium, 1000
Novartis Investigative Site
Duffel, Belgium, 2570
Novartis Investigative Site
Eupen, Belgium, 4700
Novartis Investigative Site
Framerie, Belgium, 7080
Novartis Investigative Site
Geraardsbergen, Belgium, 9500
Novartis Investigative Site
Gilly, Belgium, 6060
Novartis Investigative Site
Godinne, Belgium, 5530
Novartis Investigative Site
Gozée, Belgium, 6534
Novartis Investigative Site
Herentals, Belgium, 2200
Novartis Investigative Site
Jambes, Belgium, 5100
Novartis Investigative Site
Jette, Belgium, 1090
Novartis Investigative Site
Kortrijk, Belgium, 8500
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Liege, Belgium, 4000
Novartis Investigative Site
Liège, Belgium, 4000
Novartis Investigative Site
Malmedy, Belgium, 4960
Novartis Investigative Site
Menen, Belgium, 8930
Novartis Investigative Site
Montigny-le-tilleul, Belgium, 6110
Novartis Investigative Site
Namur, Belgium, 5000
Novartis Investigative Site
Oostende, Belgium, 8400
Novartis Investigative Site
Turnhout, Belgium, 2300
Brazil
Novartis Investigative Site
Goiania, GO, Brazil, 74605-050
Novartis Investigative Site
Juiz de Fora, MG, Brazil, 36036-110
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 22271-110
Novartis Investigative Site
Caxias do Sul, RS, Brazil, 95070-560
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90020-090
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90610-000
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90880-480
Novartis Investigative Site
São Paulo, SP, Brazil, 04023-062
Canada, Alberta
Novartis Investigative Site
Calgary, Alberta, Canada, T2V 1P9
Novartis Investigative Site
Calgary, Alberta, Canada, T2N 4N1
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Novartis Investigative Site
Kelowna, British Columbia, Canada, V1Y 1E4
Novartis Investigative Site
Vancouver, British Columbia, Canada, V5Z 3J5
Canada, Manitoba
Novartis Investigative Site
Winnipeg, Manitoba, Canada, R3C 0N2
Canada, New Brunswick
Novartis Investigative Site
Moncton, New Brunswick, Canada, E1G 1A7
Canada, Ontario
Novartis Investigative Site
Burlington, Ontario, Canada, L7N 3V2
Novartis Investigative Site
Mississauga, Ontario, Canada, L5B 4A9
Novartis Investigative Site
Newmarket, Ontario, Canada, L3Y 5G8
Novartis Investigative Site
Ottawa, Ontario, Canada, K1Y 4G2
Novartis Investigative Site
Toronto, Ontario, Canada, M5T 3A9
Novartis Investigative Site
Toronto, Ontario, Canada, M5G1N8
Novartis Investigative Site
Toronto, Ontario, Canada, M6H 3M2
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H2X 2P4
Novartis Investigative Site
Montreal, Quebec, Canada, H2L 4M1
Novartis Investigative Site
Montreal, Quebec, Canada, H4J 1C5
Novartis Investigative Site
Montreal, Quebec, Canada, H2L 2W5
Novartis Investigative Site
Sainte-Foy, Quebec, Canada, G1V 4G5
Novartis Investigative Site
Sherbrooke, Quebec, Canada, J1H 4J6
China, Hebei
Novartis Investigative Site
Shijiazhuang, Hebei, China, 050000
China, Hunan
Novartis Investigative Site
Changsha, Hunan, China, 410003
Novartis Investigative Site
Changsha City, Hunan, China, 410011
China, Liaoning
Novartis Investigative Site
Shengyang, Liaoning, China, 110016
China, Shanxi
Novartis Investigative Site
Xi'an, Shanxi, China, 710032
Novartis Investigative Site
Xi'an, Shanxi, China, 710061
China
Novartis Investigative Site
Beijing, China, 100020
Novartis Investigative Site
Beijing, China, 100034
Novartis Investigative Site
Chongqing, China, 400037
Novartis Investigative Site
Shanghai, China, 200025
Novartis Investigative Site
Shen Yang, China, 110001
Colombia
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Medellín, Colombia
Costa Rica
Novartis Investigative Site
San Francisco de Asís, Costa Rica
Novartis Investigative Site
San Jose, Costa Rica
Czech Republic
Novartis Investigative Site
Kyjov, CZE, Czech Republic, 697 70
Novartis Investigative Site
Beroun, Czech Republic
Novartis Investigative Site
Ceske Budejovice, Czech Republic, 370 87
Novartis Investigative Site
Cesky Krumlov, Czech Republic, 381 01
Novartis Investigative Site
Cvikov, Czech Republic, 471 54
Novartis Investigative Site
Karlovy Vary, Czech Republic, 360 06
Novartis Investigative Site
Karlovy Vary, Czech Republic, 360 66
Novartis Investigative Site
Kurim, Czech Republic, 66434
Novartis Investigative Site
Novy Jicin, Czech Republic, 741 01
Novartis Investigative Site
Ostrava, Czech Republic, 70030
Novartis Investigative Site
Ostrava - Hrabuvka, Czech Republic, 70030
Novartis Investigative Site
Praha 6, Czech Republic, 169 00
Novartis Investigative Site
Prerov, Czech Republic, 75000
Novartis Investigative Site
Rokycany, Czech Republic, 337 22
Novartis Investigative Site
Rudna, Czech Republic, 25219
Novartis Investigative Site
Strakonice, Czech Republic, 38601
Novartis Investigative Site
Teplice, Czech Republic, 415 01
Novartis Investigative Site
Zatec, Czech Republic, 438 01
Denmark
Novartis Investigative Site
Aalborg, Denmark, DK-9100
Novartis Investigative Site
Copenhagen NV, Denmark, DK-2400
Novartis Investigative Site
Hellerup, Denmark, DK-2900
Novartis Investigative Site
Helsingor, Denmark, DK-3000
Novartis Investigative Site
Hvidovre, Denmark, DK-2650
Novartis Investigative Site
Odense C, Denmark, DK-5000
Novartis Investigative Site
Århus, Denmark, DK-8000
Estonia
Novartis Investigative Site
Rakvere, Estonia, 44310
Novartis Investigative Site
Tallinn, Estonia, 13619
Novartis Investigative Site
Tartu, Estonia, 51014
Finland
Novartis Investigative Site
Helsinki, Finland, 00029
Novartis Investigative Site
HUS, Finland, 00029
Novartis Investigative Site
Jyvaskyla, Finland, 40100
Novartis Investigative Site
Pori, Finland, FIN-28500
Novartis Investigative Site
Porvoo, Finland, FIN-06200
Novartis Investigative Site
Tampere, Finland, FIN-33521
Novartis Investigative Site
Turku, Finland, FIN-20100
France
Novartis Investigative Site
Beuvry, France, 62660
Novartis Investigative Site
Bourges, France, 18000
Novartis Investigative Site
Ferolles-Attily, France, 77150
Novartis Investigative Site
Lyon cedex 04, France, 69317
Novartis Investigative Site
Montpellier, France, 34059
Novartis Investigative Site
Nantes, France, 44000
Novartis Investigative Site
Nice Cedex 1, France, 06602
Novartis Investigative Site
Ollioules Cedex, France, 83192
Novartis Investigative Site
Paris, France, 75006
Novartis Investigative Site
Perpignan Cedex, France, 66025
Novartis Investigative Site
Pessac, France, 33604
Novartis Investigative Site
Reims, France, 51092
Novartis Investigative Site
St Michel, France, 16470
Novartis Investigative Site
Vandoeuvre les Nancy, France, 54511
Germany
Novartis Investigative Site
Bad Woerishofen, Germany, 86825
Novartis Investigative Site
Berlin, Germany, 13086
Novartis Investigative Site
Berlin, Germany, 13581
Novartis Investigative Site
Berlin, Germany, 10367
Novartis Investigative Site
Berlin, Germany, 13507
Novartis Investigative Site
Berlin, Germany, 12687
Novartis Investigative Site
Berlin, Germany, 13057
Novartis Investigative Site
Berlin, Germany, 10969
Novartis Investigative Site
Berlin, Germany, 12043
Novartis Investigative Site
Berlin, Germany, 14050
Novartis Investigative Site
Bonn, Germany, 53123
Novartis Investigative Site
Bonn, Germany, 53119
Novartis Investigative Site
Borstel, Germany, 23845
Novartis Investigative Site
Dachau, Germany, 85221
Novartis Investigative Site
Euskirchen, Germany, 53879
Novartis Investigative Site
Frankfurt, Germany, 60596
Novartis Investigative Site
Fürstenwalde/Spree, Germany, 15517
Novartis Investigative Site
Güstrow, Germany, 18273
Novartis Investigative Site
Hamburg, Germany, 20357
Novartis Investigative Site
Hamburg, Germany, 20354
Novartis Investigative Site
Hamburg, Germany, 22305
Novartis Investigative Site
Hamburg, Germany, 22299
Novartis Investigative Site
Hoyerswerda, Germany, 02977
Novartis Investigative Site
Landsberg, Germany, 86899
Novartis Investigative Site
Leipzig, Germany, 04207
Novartis Investigative Site
Mainz, Germany, D-55101
Novartis Investigative Site
Marburg, Germany, 35037
Novartis Investigative Site
Muenchen, Germany, 81243
Novartis Investigative Site
Muenchen, Germany, 80539
Novartis Investigative Site
Muenchen, Germany, 80331
Novartis Investigative Site
Muenchen, Germany, 81677
Novartis Investigative Site
München, Germany, 80335
Novartis Investigative Site
Neu-Ulm, Germany, 89231
Novartis Investigative Site
Neumünster, Germany, 24534
Novartis Investigative Site
Neuss, Germany, 41462
Novartis Investigative Site
Oranienburg, Germany, 16515
Novartis Investigative Site
Radebeul, Germany, 01445
Novartis Investigative Site
Ratingen, Germany, 40878
Novartis Investigative Site
Rüdersdorf, Germany, 15562
Novartis Investigative Site
Teterow, Germany, 17166
Novartis Investigative Site
Ulm, Germany, 89081
Novartis Investigative Site
Wedel, Germany, 22880
Novartis Investigative Site
Witten, Germany, 58452
Hungary
Novartis Investigative Site
Budapest, Hungary, 1125
Novartis Investigative Site
Cegled, Hungary, 2700
Novartis Investigative Site
Debrecen, Hungary, 4032
Novartis Investigative Site
Deszk, Hungary, 6772
Novartis Investigative Site
Mosonmagyarovar, Hungary, 9200
Novartis Investigative Site
Nyiregyhaza, Hungary, 4400
Novartis Investigative Site
Sopron, Hungary, 9400
Novartis Investigative Site
Szarvas, Hungary, 5540
Novartis Investigative Site
Tatabanya, Hungary, 2800
Novartis Investigative Site
Torokbalint, Hungary, 2045
Iceland
Novartis Investigative Site
Reykjavik, Iceland, IS-109
India
Novartis Investigative Site
Hyderabad, Andhra Pradesh, India, 500004
Novartis Investigative Site
Hyderabad, Andhra Pradesh, India, 500012
Novartis Investigative Site
New Delhi, Delhi, India, 110029
Novartis Investigative Site
Ahmedabad, Gujrat-India, India, 380054
Novartis Investigative Site
Ahmedabad, Gujrat, India, 380009
Novartis Investigative Site
Bangalore, Karnataka, India, 560002
Novartis Investigative Site
Bangalore, Karnataka, India, 560 002
Novartis Investigative Site
Mangalore, Karnataka, India, 575001
Novartis Investigative Site
Calicut, Kerala, India, 673008
Novartis Investigative Site
Trivandrum, Kerala, India, 695011
Novartis Investigative Site
Indore, Madhya Pradesh, India, 452001
Novartis Investigative Site
Noida, New Delhi, India, 201301
Novartis Investigative Site
Jaipur, Rajasthan, India, 302023
Novartis Investigative Site
Coimbatore, Tamil Nadu, India, 641 002
Novartis Investigative Site
Vellore, Tamil Nadu, India, 632004
Novartis Investigative Site
Nagpur - Maharashtra, India, 440012
Novartis Investigative Site
Nagpur - Maharastra, India, 400 012
Novartis Investigative Site
Panjim, India, 403002
Israel
Novartis Investigative Site
Ashkelon, Israel, 78278
Novartis Investigative Site
Jerusalem, Israel, 91120
Novartis Investigative Site
Ramat Gan, Israel, 52621
Novartis Investigative Site
Rehovot, Israel, 76100
Novartis Investigative Site
Tel-Aviv, Israel, 64239
Italy
Novartis Investigative Site
Acquaviva delle Fonti, BA, Italy, 70021
Novartis Investigative Site
Bari, BA, Italy, 70124
Novartis Investigative Site
Bergamo, BG, Italy, 24128
Novartis Investigative Site
Brescia, BS, Italy, 25127
Novartis Investigative Site
Catanzaro, CZ, Italy, 88100
Novartis Investigative Site
Cona, FE, Italy, 44100
Novartis Investigative Site
Cassino, FR, Italy, 03043
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Milano, MI, Italy, 20126
Novartis Investigative Site
Milano, MI, Italy, 20157
Novartis Investigative Site
Milano, MI, Italy, 20142
Novartis Investigative Site
Modena, MO, Italy, 41100
Novartis Investigative Site
Palermo, PA, Italy, 90146
Novartis Investigative Site
Pordenone, PN, Italy, 33170
Novartis Investigative Site
Prato, PO, Italy, 59100
Novartis Investigative Site
Parma, PR, Italy, 43100
Novartis Investigative Site
Roma, RM, Italy, 00168
Novartis Investigative Site
Roma, RM, Italy, 00161
Novartis Investigative Site
Roma, RM, Italy, 00133
Novartis Investigative Site
Roma, RM, Italy, 00163
Novartis Investigative Site
Cava Dei Tirreni, SA, Italy, 84013
Novartis Investigative Site
Siena, SI, Italy, 53100
Novartis Investigative Site
Teramo, TE, Italy, 64100
Novartis Investigative Site
Orbassano, TO, Italy, 10043
Novartis Investigative Site
Trieste, TS, Italy, 34149
Novartis Investigative Site
Cuasso al Monte, VA, Italy, 21050
Novartis Investigative Site
Verona, VR, Italy, 37126
Novartis Investigative Site
Napoli, Italy, 80131
Novartis Investigative Site
Pisa, Italy, 56124
Latvia
Novartis Investigative Site
Riga, LV, Latvia, LV-1038
Novartis Investigative Site
Riga, Latvia, 1002
Lithuania
Novartis Investigative Site
Kaunas, Lithuania, 44320
Novartis Investigative Site
Klaipeda, Lithuania, LT-92231
Novartis Investigative Site
Siauliai, Lithuania, LT-76231
Novartis Investigative Site
Utena, Lithuania, LT-28151
Novartis Investigative Site
Vilnius, Lithuania, LT-08661
Mexico
Novartis Investigative Site
Pachuca, Hidalgo, Mexico, 42090
Novartis Investigative Site
Guadalajara, Jalisco, Mexico, 44100
Novartis Investigative Site
Guadalajara, Jalisco, Mexico, 44280
Novartis Investigative Site
Monterrey, Nuevo León, Mexico, 64450
Novartis Investigative Site
San Luis Potosí, Mexico, 78218
Netherlands
Novartis Investigative Site
Almelo, Netherlands, 7609 PP
Novartis Investigative Site
Breda, Netherlands, 4819 EV
Novartis Investigative Site
Eindhoven, Netherlands, 5623 EJ
Novartis Investigative Site
Enschede, Netherlands, 7513 ER
Novartis Investigative Site
Rotterdam, Netherlands, 3045 PM
Novartis Investigative Site
Sneek, Netherlands, 8601 ZK
Novartis Investigative Site
Zwolle, Netherlands, 8011 JW
Peru
Novartis Investigative Site
Cercado de Lima, Lima, Peru, 01
Novartis Investigative Site
Jesus Maria, Lima, Peru, 11
Novartis Investigative Site
La Victoria, Lima, Peru, 13
Novartis Investigative Site
Miraflores, Lima, Peru, 18
Novartis Investigative Site
San Borja, Lima, Peru, 41
Novartis Investigative Site
San Isidro, Lima, Peru, 27
Novartis Investigative Site
San Martin de Porres, Lima, Peru, 31
Novartis Investigative Site
San Miguel, Lima, Peru, 32
Novartis Investigative Site
Santiago de Surco, Lima, Peru, 33
Philippines
Novartis Investigative Site
Quezon City, Metro Manila, Philippines, 1109
Novartis Investigative Site
Quezon City, Metro Manila, Philippines, 1104
Novartis Investigative Site
Quezon City, Philippines, 1101
Novartis Investigative Site
Quezon City, Philippines, 1100
Poland
Novartis Investigative Site
Gdansk, Poland, 80-169
Novartis Investigative Site
Gdansk, Poland, 80-847
Novartis Investigative Site
Katowice, Poland, 40-752
Novartis Investigative Site
Krakow, Poland, 31-202
Novartis Investigative Site
Krakow, Poland, 31-455
Novartis Investigative Site
Krakow, Poland, 31-159
Novartis Investigative Site
Warszawa, Poland, 02-341
Novartis Investigative Site
Warszawa, Poland, 01-138
Novartis Investigative Site
Wroclaw, Poland, 50-044
Portugal
Novartis Investigative Site
Amadora, Portugal, 2720-276
Novartis Investigative Site
Coimbra, Portugal, 3000-075
Novartis Investigative Site
Coimbra, Portugal, 3041-853
Novartis Investigative Site
Lisboa, Portugal, 1649-035
Novartis Investigative Site
Lisboa, Portugal, 1769-001
Novartis Investigative Site
Lisboa, Portugal, 1169-024
Novartis Investigative Site
Porto, Portugal, 4200-319
Romania
Novartis Investigative Site
Bucharest, District 3, Romania, 030303
Novartis Investigative Site
Brasov, Jud. Brasov, Romania, 500118
Novartis Investigative Site
Constanta, Jud. Constanta, Romania, 900002
Novartis Investigative Site
Iasi, Jud. Iasi, Romania, 700115
Novartis Investigative Site
Bucharest, Romania, 060011
Novartis Investigative Site
Cluj-Napoca, Romania, 400371
Russian Federation
Novartis Investigative Site
Kazan, Tatarstan Republic, Russian Federation, 420015
Novartis Investigative Site
Chelyabinsk, Russian Federation, 454047
Novartis Investigative Site
Chelyabinsk, Russian Federation, 454021
Novartis Investigative Site
Ekaterinburg, Russian Federation, 620109
Novartis Investigative Site
Ekaterinburg, Russian Federation, 620219
Novartis Investigative Site
Kazan, Russian Federation, 420015
Novartis Investigative Site
Moscow, Russian Federation, 119992
Novartis Investigative Site
Moscow, Russian Federation, 105229
Novartis Investigative Site
Moscow, Russian Federation, 121609
Novartis Investigative Site
Moscow, Russian Federation, 121359
Novartis Investigative Site
Moscow, Russian Federation, 115446
Novartis Investigative Site
Moscow, Russian Federation, 115280
Novartis Investigative Site
Moscow, Russian Federation, 105077
Novartis Investigative Site
Samara, Russian Federation, 443079
Novartis Investigative Site
Sankt-Peterburg, Russian Federation, 197022
Novartis Investigative Site
St. Petersburg, Russian Federation, 194354
Novartis Investigative Site
St.-Petersburg, Russian Federation, 193231
Slovakia
Novartis Investigative Site
Bratislava, Slovak Republic, Slovakia, 821 06
Novartis Investigative Site
Kosice, Slovak Republic, Slovakia, 041 90
Novartis Investigative Site
Spisska Nova Ves, Slovak Republic, Slovakia, 052 01
Novartis Investigative Site
Bratislava, Slovakia, 826 06
Novartis Investigative Site
Kosice, Slovakia, 040 01
Novartis Investigative Site
Lucenec, Slovakia, 984 39
Novartis Investigative Site
Nove Zamky, Slovakia, 940 01
Novartis Investigative Site
Poprad, Slovakia, 058 01
South Africa
Novartis Investigative Site
Bloemfontein, South Africa, 9317
Novartis Investigative Site
Bloemfontein, South Africa, 9301
Novartis Investigative Site
Cape Town, South Africa, 8001
Novartis Investigative Site
Durban, South Africa, 4001
Spain
Novartis Investigative Site
Jerez de La Frontera, Andalucia, Spain, 11407
Novartis Investigative Site
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site
Sanlúcar de Barrameda, Andalucia, Spain, 11540
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41009
Novartis Investigative Site
Gijon, Asturias, Spain, 33290
Novartis Investigative Site
Illescas, Castilla la Mancha, Spain, 45200
Novartis Investigative Site
Valladolid, Castilla y Leon, Spain, 47011
Novartis Investigative Site
Barcelona, Cataluña, Spain, 08041
Novartis Investigative Site
Barcelona, Cataluña, Spain, 08003
Novartis Investigative Site
Barcelona, Cataluña, Spain, 08036
Novartis Investigative Site
Salt, Cataluña, Spain, 17190
Novartis Investigative Site
Sant Boi de Llobregat, Cataluña, Spain, 08830
Novartis Investigative Site
Terrassa, Cataluña, Spain, 08221
Novartis Investigative Site
Vic, Cataluña, Spain, 08500
Novartis Investigative Site
Alicante, Comunidad Valenciana, Spain, 03114
Novartis Investigative Site
Alzira, Comunidad Valenciana, Spain, 46600
Novartis Investigative Site
Requena, Comunidad Valenciana, Spain, 46340
Novartis Investigative Site
Caceres, Extremadura, Spain, 10003
Novartis Investigative Site
Mérida, Extremadura, Spain, 06800
Novartis Investigative Site
Plasencia, Extremadura, Spain, 10600
Novartis Investigative Site
La Coruna, Galicia, Spain, 15006
Novartis Investigative Site
Lugo, Galicia, Spain, 27003
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain, 15706
Novartis Investigative Site
Pozuelo de Alarcón, Madrid, Spain, 28223
Novartis Investigative Site
Madrid, Spain, 28007
Novartis Investigative Site
Madrid, Spain, 28040
Sweden
Novartis Investigative Site
Göteborg, Sweden, 412 63
Novartis Investigative Site
Göteborg, Sweden, 413 45
Novartis Investigative Site
Luleå, Sweden, SE-971 80
Novartis Investigative Site
Lund, Sweden, SE-221 85
Novartis Investigative Site
Malmö, Sweden, 205 02
Novartis Investigative Site
Skellefteå, Sweden, SE 931 32
Novartis Investigative Site
Stockholm, Sweden, S-171 76
Novartis Investigative Site
Sundsvall, Sweden, 851 86
Switzerland
Novartis Investigative Site
Faltigberg-Wald, ZH, Switzerland, 8639
Novartis Investigative Site
Bern, Switzerland, 3013
Novartis Investigative Site
Crans-Montana, Switzerland, 3963
Novartis Investigative Site
Lausanne, Switzerland, 1011
Novartis Investigative Site
St. Gallen, Switzerland, 9007
Novartis Investigative Site
Thun, Switzerland, 3600
Novartis Investigative Site
Winterthur, Switzerland, 8401
Novartis Investigative Site
Zuerich, Switzerland, 8032
Taiwan
Novartis Investigative Site
Taichung, Taiwan, 40447
Novartis Investigative Site
Taichung, Taiwan, 40705
Novartis Investigative Site
Taipei, Taiwan, 10002
Novartis Investigative Site
Taipei, Taiwan, 110
Novartis Investigative Site
Taipei County, Taiwan
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10700
Novartis Investigative Site
Chiang Mai, Thailand, 50200
Novartis Investigative Site
Khon Kaen, Thailand, 40002
Novartis Investigative Site
Songkla, Thailand, 90110
Turkey
Novartis Investigative Site
Ankara, Turkey, 06100
Novartis Investigative Site
Canakkale, Turkey, 17100
Novartis Investigative Site
Diskapi / Ankara, Turkey, 06110
Novartis Investigative Site
Emek / Ankara, Turkey, 06510
Novartis Investigative Site
Gaziantep, Turkey, 27070
Novartis Investigative Site
Isparta, Turkey, 32100
Novartis Investigative Site
Istanbul, Turkey
Novartis Investigative Site
Izmir, Turkey, 35340
Novartis Investigative Site
Kahramanmaras, Turkey, 46100
Novartis Investigative Site
Kecioren / Ankara, Turkey, 06280
Novartis Investigative Site
Kozlu / Zonguldak, Turkey, 67600
Novartis Investigative Site
Malatya, Turkey, 44280
Novartis Investigative Site
Mersin, Turkey, 33079
Novartis Investigative Site
Yenisehir/Izmir, Turkey, 35110
United Kingdom
Novartis Investigative Site
Swansea, England, United Kingdom, SA6 6NL
Novartis Investigative Site
Newcastle Upon Tyne, Newcastle, United Kingdom, NE7 7DN
Novartis Investigative Site
Ash Vale, Surrey, United Kingdom, GU12 5BA
Novartis Investigative Site
Crawley, West Sussex, United Kingdom, RH10 7DX
Novartis Investigative Site
Belfast, United Kingdom, BT7 2BE
Novartis Investigative Site
Bexhill-on-Sea, United Kingdom, TN40 1JJ
Novartis Investigative Site
Bradford, United Kingdom, BD9 6RJ
Novartis Investigative Site
Bristol, United Kingdom, BS10 5NB
Novartis Investigative Site
Cambridge, United Kingdom, CB7 5JD
Novartis Investigative Site
Lancashire, United Kingdom, B13 6TL
Novartis Investigative Site
Lancashire, United Kingdom, FY3 7EN
Novartis Investigative Site
Liverpool, United Kingdom, L9 7AL
Novartis Investigative Site
London, United Kingdom, SW3 6PH
Novartis Investigative Site
London, United Kingdom, W1G 8HU
Novartis Investigative Site
London, United Kingdom, E2 9JX
Novartis Investigative Site
Newport, United Kingdom, P030 5TG
Novartis Investigative Site
Stockport, United Kingdom, SK8 6LU
Novartis Investigative Site
Stockport, United Kingdom, SK4 4NX
Novartis Investigative Site
Surrey, United Kingdom, KT16 0PZ
Novartis Investigative Site
Warminster, United Kingdom, BA12 9AA
Novartis Investigative Site
Watford, United Kingdom, WD25 0EA
Novartis Investigative Site
Windsor, United Kingdom, SL4 3DP
Venezuela
Novartis Investigative Site
Valencia, Estado Carabobo, Venezuela, 2005
Novartis Investigative Site
Barquisimeto, Estado Lara, Venezuela, 3002
Novartis Investigative Site
Maracaibo, Estado Zulia, Venezuela, 4002
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00845728     History of Changes
Other Study ID Numbers: CQAB149B2348, 2008-007944-33
Study First Received: February 15, 2009
Results First Received: July 3, 2013
Last Updated: September 16, 2013
Health Authority: United States: Food and Drug Administration
Austria: Federal Office for Safety in Health Care
Slovakia: State Institute for Drug Control
Canada: Health Canada
Israel: Ministry of Health
Spain: Spanish Agency of Medicines
Estonia: The State Agency of Medicine
Lithuania: State Medicine Control Agency - Ministry of Health
Finland: Finnish Medicines Agency
Belgium: Federal Agency for Medicinal Products and Health Products
United Kingdom: Medicines and Healthcare Products Regulatory Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
India: Drugs Controller General of India
Hungary: National Institute of Pharmacy
Iceland: Icelandic Medicines Control Agency
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Australia: Department of Health and Ageing Therapeutic Goods Administration
Denmark: Danish Medicines Agency
Czech Republic: State Institute for Drug Control
Turkey: Ministry of Health
Latvia: State Agency of Medicines
Philippines: Bureau of Food and Drugs
Russia: FSI Scientific Center of Expertise of Medical Application
Germany: Federal Institute for Drugs and Medical Devices
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Portugal: National Authority of Medicines and Health Products (INFARMED, I.P.)
Taiwan: Department of Health
Sweden: Medical Products Agency
Switzerland: Swissmedic
Romania: National Medicines Agency
Peru: Instituto Nacional de Salud
Costa Rica: Ministry of Health Costa Rica
Italy: The Italian Medicines Agency
South Africa: Medicines Control Council
China: Food and Drug Administration
Venezuela: Ministry of Health and Social Development
Brazil: National Health Surveillance Agency
Thailand: Food and Drug Administration
Mexico: National Institute of Public Health, Health Secretariat
New Zealand: Ministry of Health

Keywords provided by Novartis:
Indacaterol
Tiotropium
COPD

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
Tiotropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 19, 2014